Meeting
2016 ASCO Annual Meeting
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Authors
Archana Anantharaman
University of California, San Francisco, San Francisco, CA
Archana Anantharaman , Terence W. Friedlander , David Lu , Rachel Krupa , Gayatri Premasekharan , Jeffrey Hough , Matthew Edwards , Ryon Graf , Adam Jendrisak , Jessica Louw , Lyndsey Dugan , Dena C. Marrinucci , Ryan Vance Dittamore , Pamela Paris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4527)
DOI
10.1200/JCO.2016.34.15_suppl.4527
Abstract #
4527
Poster Bd #
150
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.
First Author: Archana Anantharaman
Poster
2024 ASCO Genitourinary Cancers Symposium
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
First Author: Mathilde Cancel
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre